CAM Use May Affect Breast Cancer Patients' Chemo Decisions

This article originally appeared here.
Share this content:
CAM Use May Affect Breast Cancer Patients' Chemo Decisions
CAM Use May Affect Breast Cancer Patients' Chemo Decisions

FRIDAY, May 13, 2016 (HealthDay News) -- Women with early-stage breast cancer who utilize complementary and alternative medicine (CAM) may delay recommended chemotherapy, according to research published online May 12 in JAMA Oncology.

Heather Greenlee, Ph.D., assistant professor of epidemiology at the Columbia University Mailman School of Public Health in New York City, and colleagues studied 685 women with early-stage breast cancer, all under the age of 70. Of all the women in the study, 87 percent said they used some type of CAM, most commonly dietary supplements and mind-body practices. Many women used two CAM therapies, and 38 percent used three or more.

In all, 306 women were advised to undergo chemotherapy. After a year, 89 percent of these women had started treatment. Among the other women, for whom chemotherapy was optional, only 36 percent opted for treatment. Use of dietary supplements and high CAM index scores were related to the decision whether or not to have chemotherapy, while the use of mind-body practices was not related to starting chemotherapy. No association between starting chemotherapy and alternative therapy was found among women for whom chemotherapy was optional.

"A cautious interpretation of results may suggest to oncologists that it is beneficial to ascertain CAM use among their patients, especially dietary supplement use, and to consider CAM use as a potential marker of patients at risk of not initiating clinically indicated chemotherapy," the authors conclude.

Abstract
Full Text
Editorial

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

Gene Tx Approved for Certain Types of B-Cell Lymphoma

Gene Tx Approved for Certain Types of B-Cell ...

First such treatment for certain types of non-Hodgkin lymphoma

Uninsurance Down by One-Third for Cancer Diagnoses in 2014

Uninsurance Down by One-Third for Cancer Diagnoses in ...

Significant decreases in uninsurance seen across all stages and sites assessed in first year of ACA

Diabetes Ups Risk of MACE in Acute Coronary Syndromes

Diabetes Ups Risk of MACE in Acute Coronary ...

Diabetes, but not pre-diabetes, tied to increased risk of major adverse cardiac events in adjusted model

is free, fast, and customized just for you!

Already a member?

Sign In Now »